QUIRIS Healthcare

Recent papers from QUIRIS Healthcare

1. Cost-effectiveness analysis of molecular reflex testing-based targeted therapy in non-small cell lung cancer from a German healthcare payer perspective using a decision tree modelCost Effectiveness and Resource Allocation · 2026
2. Complement inhibitor therapy in atypical hemolytic uremic syndrome (aHUS): evaluating the economic impact of introducing eculizumab biosimilars in GermanyBMC Nephrology · 2026
3. Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responsesClinical Cancer Research · 2026
4. Uncovering gaps in personalised lung cancer care in Germany: a white spot analysisBMC Cancer · 2025
5. Comparative Assessment of Nutraceuticals for Supporting Skin HealthNutraceuticals · 2025
6. Caseload, clinical spectrum and economic burden of infectious diseases in patients discharged from hospitals in GermanyInfection · 2025
7. Third-line multiple myeloma treatment of inpatients in a German cancer center: analysis of potential cost savings due to decreased renal insufficiencyCost Effectiveness and Resource Allocation · 2025
8. Economic effects of next-generation sequencing diagnostics in unspecific sepsis patients – a budget impact analysis from the healthcare providers’ perspective in GermanyEuropean Journal of Clinical Microbiology & Infectious Diseases · 2024
9. How to optimize the CAR-T Cell therapy process? A group concept mapping analysis of preconditions for a frictionless process from a German multistakeholder perspectiveFrontiers in Oncology · 2024
10. Restoration of the Ultrastructural Integrity of the Dermal Collagen Network by 12-Week Ingestion of Special Collagen PeptidesDermatology and Therapy · 2024
11. Attributable mortality of candidemia – Results from the ECMM Candida III multinational European Observational Cohort StudyJournal of Infection · 2024
12. Time‐dependent cost comparison and health economic impact analysis of second‐line interventions for transplant‐ineligible patients with relapsed or refractory diffuse large B cell lymphomaEuropean Journal Of Haematology · 2024
13. A retrospective budget impact analysis of fidaxomicin treatment for Clostridioides difficile infections (CDI) in GermanyExpert Review of Pharmacoeconomics & Outcomes Research · 2024
14. Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in GermanyCost Effectiveness and Resource Allocation · 2024
15. Economic effects of treating postpartum hemorrhage with vacuum-induced hemorrhage control devices – A budget impact analysis of the Jada® System in the German obstetrics settingEuropean Journal of Obstetrics & Gynecology and Reproductive Biology · 2024
16. Cost‐effectiveness analysis of transplant‐ineligible relapsed or refractory diffuse large B‐cell lymphoma treatment options—Experience of the efficiency frontier approachEuropean Journal Of Haematology · 2023
17. Cost Comparison of Treatment Alternatives for Pleural Effusion and Ascites from a Payer Perspective: Are There Cost Savings from Indwelling Catheters?Journal of Palliative Medicine · 2023
18. Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin – A real-world data and retrospective cost analysisJournal of Infection and Public Health · 2023
19. Health economic analysis of patients treated with isavuconazole in a German comprehensive cancer centreMycoses · 2023
20. Health Economic Aspects of Platelet Concentrates: Comparing Cost and Reimbursement of Pathogen Inactivated and Conventional Platelet Concentrates in a German Comprehensive Cancer CenterOncology Research and Treatment · 2023